These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38546612)

  • 1. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
    Fernandez-Martinez A; Rediti M; Tang G; Pascual T; Hoadley KA; Venet D; Rashid NU; Spears PA; Islam MN; El-Abed S; Bliss J; Lambertini M; Di Cosimo S; Huobe J; Goerlitz D; Hu R; Lucas PC; Swain SM; Sotiriou C; Perou CM; Carey LA
    JAMA Oncol; 2024 May; 10(5):603-611. PubMed ID: 38546612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 h + HER2- breast cancer: a retrospective analysis.
    Kook Y; Lee YJ; Chu C; Jang JS; Baek SH; Bae SJ; Cha YJ; Gong G; Jeong J; Lee SB; Ahn SG
    Breast Cancer Res; 2024 Nov; 26(1):154. PubMed ID: 39506855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Factors Associated With Pathological Complete Response in Patients With HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy.
    Stjepanovic N; Kumar S; Jerzak KJ; Trudeau M; Warner E; Cao X; Eisen A; Tran W; Pezo RC
    Clin Breast Cancer; 2024 Dec; 24(8):e723-e730. PubMed ID: 39244392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antioxidants for female subfertility.
    Showell MG; Mackenzie-Proctor R; Jordan V; Hart RJ
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD007807. PubMed ID: 32851663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilar monoclonal antibodies for cancer treatment in adults.
    Galvao TF; Livinalli A; Lopes LC; Zimmermann IR; Silva MT
    Cochrane Database Syst Rev; 2024 Nov; 11(11):CD013539. PubMed ID: 39607013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antioxidants for female subfertility.
    Showell MG; Mackenzie-Proctor R; Jordan V; Hart RJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD007807. PubMed ID: 28752910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].
    de Azambuja E; Piccart-Gebhart M; Fielding S; Townend J; Hillman DW; Colleoni M; Roylance R; Kelly CM; Lombard J; El-Abed S; Choudhury A; Korde L; Vicente M; Chumsri S; Rodeheffer R; Ellard SL; Wolff AC; Holtschmidt J; Lang I; Untch M; Boyle F; Xu B; Werutsky G; Tujakowski J; Huang CS; Baruch NB; Bliss J; Ferro A; Gralow J; Kim SB; Kroep JR; Krop I; Kuemmel S; McConnell R; Moscetti L; Knop AS; van Duijnhoven F; Gomez H; Cameron D; Di Cosimo S; Gelber RD; Moreno-Aspitia A
    ESMO Open; 2024 Nov; 9(11):103938. PubMed ID: 39418883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial.
    van 't Veer LJ; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; Van de Velde CJH; Kleijn M; Dreezen C; Menicucci AR; Audeh W; Liefers GJ
    JAMA Netw Open; 2024 Nov; 7(11):e2447530. PubMed ID: 39602119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interventions for supporting pregnant women's decision-making about mode of birth after a caesarean.
    Horey D; Kealy M; Davey MA; Small R; Crowther CA
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD010041. PubMed ID: 23897547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of inflammatory blood markers and pathological complete response in HER2-positive breast cancer: a retrospective single-center cohort study.
    Chen X; Cai Q; Deng L; Chen M; Xu M; Chen L; Lin Y; Li Y; Wang Y; Chen H; Liu S; Wu J; Tong X; Fu F; Wang C
    Front Immunol; 2024; 15():1465862. PubMed ID: 39628488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early-stage Hodgkin's lymphoma.
    Goldkuhle M; Kreuzberger N; von Tresckow B; Eichenauer DA; Specht L; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2024 Dec; 12(12):CD007110. PubMed ID: 39620432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial.
    Chen XC; Jiao DC; Qiao JH; Wang CZ; Sun XF; Lu ZD; Li LF; Zhang CJ; Yan M; Wei Y; Chen B; Feng YQ; Deng M; Ma MD; Plichta JK; He YW; Liu ZZ
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39612919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
    Llovet JM; Kudo M; Merle P; Meyer T; Qin S; Ikeda M; Xu R; Edeline J; Ryoo BY; Ren Z; Masi G; Kwiatkowski M; Lim HY; Kim JH; Breder V; Kumada H; Cheng AL; Galle PR; Kaneko S; Wang A; Mody K; Dutcus C; Dubrovsky L; Siegel AB; Finn RS;
    Lancet Oncol; 2023 Dec; 24(12):1399-1410. PubMed ID: 38039993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological treatments in panic disorder in adults: a network meta-analysis.
    Guaiana G; Meader N; Barbui C; Davies SJ; Furukawa TA; Imai H; Dias S; Caldwell DM; Koesters M; Tajika A; Bighelli I; Pompoli A; Cipriani A; Dawson S; Robertson L
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD012729. PubMed ID: 38014714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis.
    Curry N; Davenport R; Thomas H; Fox E; Lucas J; Evans A; Massou E; Sharma R; Shanmugaranjan S; Rourke C; Newton A; Deary A; Dallas N; Fitzpatrick-Creamer C; Podbielski JM; Wade CE; Edwards A; Benger J; Morris S; Cotton BA; Piercy J; Green L; Brohi K; Stanworth S
    Health Technol Assess; 2024 Nov; 28(76):1-69. PubMed ID: 39545850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.
    Harnan S; Kearns B; Scope A; Schmitt L; Jankovic D; Hamilton J; Srivastava T; Hill H; Ku CC; Ren S; Rothery C; Bojke L; Sculpher M; Woods B
    Health Technol Assess; 2024 Oct; 28(73):1-230. PubMed ID: 39487661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer.
    van der Voort A; van der Hoogt KJJ; Wessels R; Schipper RJ; Wesseling J; Sonke GS; Mann RM
    Eur Radiol; 2024 Dec; 34(12):7994-8004. PubMed ID: 38967659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.